Proactive Investors - Run By Investors For Investors

Archer Exploration prints human antibodies on graphene biosensors

The graphite from Archer’s Campoona Graphite Deposit in South Australia is structurally near perfect, even after mechanical and chemical processing.
An antibody ink formulation printed and patterned onto a resin-coated paper substrate
An antibody ink formulation printed and patterned onto a resin-coated paper substrate

Archer Exploration Ltd (ASX:AXE) has successfully printed and patterned ink formulations of human antibodies on graphene-based biosensor components derived from the company’s Campoona graphite.

Ink formulations comprised primarily of human antibody immunoglobulin G (IgG) as the active constituent were successfully prepared and printed using proprietary methods.

The IgG inks were printed on resin-coated paper and a number of graphene-based electrodes and were able to withstand the chemical and physical processes in the formulation, printing, and post-printing steps.

Background

Biological sensor devices are used in the detection and diagnosis of disease. The uniqueness of a biosensor is that its critical components are integrated into one sensor.

One of the biggest challenges to printable biosensors involves the scalable fabrication of integrated componentry capable of multiplexing – detecting a number of different diseases simultaneously using the same specimen.

The development of printable biosensors is envisioned to impact industries servicing human health, including point of care diagnostics and medical devices.

 

Archer CEO Dr Mohammad Choucair said: “We were able to formulate inks incorporating process compatible biomaterials provided by our German Biotech partners, and the team at the ARC Graphene Hub were able to print them on a number of our biosensor components.

“This concerted effort addressed a key technical barrier to realising a globally competitive biosensor, that of digitising the manufacturing of critical biosensor componentry that could allow for multiplexing.

“It has provided strong support for a number of claims in our provisional patent, which legally protects this competitive advantage and provides a means for commercial exploitation of the IP.”

Intellectual property and provisional patent publication

Archer’s provisional patent on the biosensor technology IP has been published in the Australian Official Journal of Patents.

The company is the sole applicant of the provisional patent, maintaining 100% ownership of the biosensor technology IP. Archer has until 15 February 2020 to consider maturing the application to a full patent.

View full AXE profile View Profile

Archer Exploration Limited Timeline

Related Articles

1549368147_Danakali-SOP.jpg
April 29 2019
Kore Potash has completed a definitive feasibility study on the Kola project
Inspection at Cangai property
April 28 2019
The company has the Cangai Copper Project in northern NSW as its flagship asset.
1557833995_Kincora-drill-rig.jpg
May 14 2019
Kincora has a huge swathe of ground in Mongolia which it is now getting ready to drill

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use